Cancer Institute, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China.
Cancer Control. 2024 Jan-Dec;31:10732748241276674. doi: 10.1177/10732748241276674.
Cancer is a major health concern in China. Understanding the epidemiology of cancer can guide the development of effective prevention and control strategies. This study aimed to comprehensively analyze the cancer burden, time trends, and attributable risk factors of cancers in China and compare them with those in India.
We utilized the GLOBOCAN database for 2022, Cancer Incidence in Five Continents (C15 plus) series, and Global Burden of Disease (GBD) 2021 to extract data on cancer incidence, mortality, disability-adjusted life years (DALYs), and risk factors. Time-trend analysis was performed using a join-point regression model. Correlations between cancer DALY rates and risk factors were analyzed using linear regression.
In 2022, China experienced 4,824,703 new cancer cases and 2,574,176 cancer-related deaths. Cancers also caused approximately 71.2 million DALYs in China in 2021. Compared with India, China has higher incidence, mortality, and DALY rates for various cancers. Breast and thyroid cancers in China have shown a rapid increase in the age-standardized incidence rate (ASIR), along with a substantial burden of lung, stomach, esophageal, and colorectal cancer. However, stomach and liver cancers in China showed a downward trend in ASIR. In 2021, diet low in milk was a major risk factor among females for colorectal cancer DALYs in China (23% of age-standardized DALYs) and India (22.9%). In China, smoking has been associated with increased DALYs due to lung cancer.
China has a heavier cancer burden than India. The heavy burden of lung, stomach, esophageal, and colorectal cancers, combined with the rising incidence of breast and thyroid cancers, pose a critical challenge to public health in China. Cancer burden may be reduced through public health initiatives that prioritize primary prevention, prompt identification, and therapeutic intervention.
癌症是中国面临的主要健康问题之一。了解癌症的流行病学情况可以指导制定有效的预防和控制策略。本研究旨在全面分析中国癌症的负担、时间趋势以及归因风险因素,并与印度进行比较。
我们利用 2022 年 GLOBOCAN 数据库、癌症发病率五大陆(C15 plus)系列和 2021 年全球疾病负担(GBD)数据,提取癌症发病率、死亡率、伤残调整生命年(DALY)和风险因素的数据。采用 Joinpoint 回归模型进行时间趋势分析。采用线性回归分析癌症 DALY 率与风险因素之间的相关性。
2022 年,中国新发癌症病例 4824703 例,癌症相关死亡病例 2574176 例。2021 年,中国癌症导致的 DALY 约为 7120 万。与印度相比,中国各种癌症的发病率、死亡率和 DALY 率更高。中国乳腺癌和甲状腺癌的年龄标准化发病率(ASIR)呈快速上升趋势,同时肺癌、胃癌、食管癌和结直肠癌的负担也很大。然而,中国胃癌和肝癌的 ASIR 呈下降趋势。2021 年,中国女性饮食中低牛奶与结直肠癌 DALY 呈正相关(占年龄标准化 DALY 的 23%),与印度(22.9%)相似。在中国,吸烟与肺癌导致的 DALY 增加有关。
中国的癌症负担比印度更重。中国肺癌、胃癌、食管癌和结直肠癌负担沉重,加上乳腺癌和甲状腺癌发病率上升,对中国的公共卫生构成了重大挑战。通过优先开展初级预防、及时发现和治疗干预等公共卫生措施,可以减轻癌症负担。